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ABSTRACT
In the United States, metastatic breast cancer kills approximately 40,000 women
and 400 men annually, and approximately 200,000 new cases of breast cancer are
diagnosed each year. Worldwide, breast cancer is the leading cause of cancer deaths
among women. Despite advances in the detection and treatment of metastatic breast
cancer, mortality rates from this disease remain high because the fact is that once
metastatic, it is virtually incurable. It is widely accepted that a major reason breast
cancer continues to exhibit recurrence after remission is that current therapies are
insufficient for targeting and eliminating therapy-resistant cancer cells. Emerging
research has demonstrated that these therapy-resistant cells possess stem cell-like
properties and are therefore commonly referred to as breast cancer stem cells (BCSCs).
A major hallmark of BCSCs is the cell surface expression of CD44 and lack of
expression of CD24, the so-called CD24-/CD44+ phenotype. Research indicates that this
dangerous and rare subpopulation of BCSCs may be responsible for cancer onset,
recurrence, and ultimately metastasis that leads to death.
Two different model systems were utilized in this research. The first was the
MCF7 cell line, a luminal A tumor subtype representative of a mildly invasive breast
ductal carcinoma with an ER+/PR+/-/HER2- immunoprofile. The second was the
MCF10A breast cancer progression model, which consists of three cell lines: MCF10A,
MCF10AT1, and MCF10CA1a. In this system, spontaneously immortalized, nonmalignant MCF10A cells were transfected with constitutively active H-Ras to form premalignant MCF10AT1 cells, which were then subcutaneously injected into mice and
allowed to metastasize in order to form the oncogenic MCF10ACA1a cell line.
This thesis presents evidence of a CD24low/-/CD44+ BCSC subpopulation within
the MCF10A breast cancer progression model system. Findings indicate that RUNX1
and RUNX2 expression levels are involved in maintaining the BCSC phenotype. Across
two different model systems, qRT-PCR analysis revealed that decreased levels of
RUNX1 expression and increased levels of RUNX2 expression are essential for the
maintenance of the BCSC subpopulation. It was also shown that low expression levels of
RUNX1 and high expression levels of RUNX2 are present in CD24low/-/CD44+ BCSCs as
compared to CD24+/CD44+ non-BCSCs. Furthermore, shRNA knockdown of RUNX1
was shown to enhance tumorigenicity, while shRNA knockdown of RUNX2 repressed
tumorigenicity in BCSCs, as measured by the tumorsphere-formation assay. This
research lays the groundwork for future investigations into the roles of RUNX1 and
RUNX2 in regulating stemness in breast cancer.
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CHAPTER 1: LITERATURE SUMMARY
Cancer Stem Cells
The existence of cancer stem cells first came to light back in the 1960’s and
1970’s when researchers studying leukemia and myeloma discovered that only a
sub-fraction of cancer cells possessed the ability to proliferate extensively [1, 2].
Over the course of the past fifteen years or so, cancer stem cells have been
shown to exist in many different types of solid tumors, including those of the
prostate, brain, skin, colon and breast [3–8]. The cancer stem cell theory posits
that only a subpopulation of cells within tumors, which have stem cell-like
properties, are capable of tumorigenesis. These cells are defined by their ability
to self-renew, give rise to differentiated progeny that constitute the bulk of the
tumor mass, and form tumors in immunocompromised mice [9, 10]. This theory
is in contrast to the traditional, stochastic model of tumorigenesis, which states
that all cells within a tumor have tumorigenic potential [11]. It is also known
that cancer stem cells are highly resistant to radiation and chemotherapy, and
have enhanced metastatic potential [12, 13]. In summary, the cancer stem cell
theory posits that only a small subpopulation of cancer cells with stem cell-like
properties are able to self-renew and sustain a tumor, similar to the way in
which adult stem cells self-renew and sustain tissues and organs. In this theory,
non-stem cancer cells are able to cause problems in the body, but it is the cancer
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stem cell subpopulation that is responsible for the sustained longevity of the
cancer.
There is still debate as to the origin of cancer stem cells. One school of
thought suggests that they originate from mutations in adult stem cells, while
other possible explanations point to mutations in progenitor cells and transit
amplifying cells as being the causative factor of their derivation. There is also
speculation that cancer stem cells may arise from mutations in fully
differentiated cells that reactivate pathways governing stemness and
transformation [17-22]. Furthermore, it has been shown that cellular signaling
pathways governing the epithelial to mesenchymal transition (EMT) are
involved in the maintenance of the cancer stem cell phenotype [23]. Indeed, it
seems possible that cancer cells with stem cell-like characteristics may have more
than one method of origin, and it is imperative to identify regulatory molecules
responsible for maintaining the cancer stem cell phenotype so that future
therapies can target and eliminate this dangerous subpopulation of cells in order
to improve patient outcomes.
Breast Cancer Stem Cells
In the US, metastatic breast cancer kills approximately 40,000 women and
400 men annually, and approximately 200,000 new cases of breast cancer are
diagnosed each year. Worldwide, breast cancer is the leading cause of cancer
deaths among women [24]. Despite advances in the detection and treatment of
metastatic breast cancer, mortality rates from this disease remain high because
2

current therapies are insufficient at targeting and eliminating therapy-resistant
breast cancer stem cells (BCSCs). A prevailing theory in the field of breast cancer
research ascertains that one of the main reasons cancers exhibit recurrence after
remission is the existence BCSCs that are chemotherapy and radiotherapy
resistant. The resistance that BCSCs have to radiation is attributed to the ability
of these cells to transition into and out of a quiescent state, while the
chemoresistance of BCSCs is related to their expression of ATP-binding cassette
(ABC) transporters, detoxifying transport pumps that normally function to
protect cells from environmental toxins. These transporters are up-regulated in
BCSCs, and two in particular have been studied extensively: breast cancer
resistance protein (ABCG2) and P-glycoprotein (MDR1). ABCG2 is known to
efflux doxorubicin, and MDR1 is known to efflux drugs such as paclitaxel. It is
the elevated expression of these types of transporters, compared to non-BCSCs,
which gives BCSCs enhanced chemoresistance [12,13].
BCSCs are characterized on the basis of three distinct abilities: selfrenewal, differentiation (the ability to form multiple lineages with non-stem cell
characteristics), and formation of tumors in immunocompromised mice [14].
There is still a good deal of controversy surrounding the definition of a breast
cancer stem cell, and which biomarkers definitively identify this subpopulation
of cells. A lack of correlation exists with respect to the biomarkers used to
identify and define BCSCs among different breast cancer cell lines and patient
tumor samples. Some of the most common biomarkers used to identify BCSCs
3

are the cluster of differentiation 24/44 (CD24-/CD44+) signature, aldehyde
dehydrogenase 1A1 (ALDH+), and SRY-box 2 (Sox2+). It is speculated that each
of these populations represents a unique subpopulation of breast cancer cells
with stem cell-like properties rather than one common and definitive BCSC
population [25]. One of the most common methods used for studying BCSCs is
isolation of the CD24-/CD44+ fraction by fluorescence activated cell sorting
(FACS).
A major way in which self-renewal ability and tumorigenicity is assessed
in the BCSC population is by subjecting BCSCs to the tumorsphere/
mammosphere assay. In this assay, single isolated CD24-/CD44+ BCSCs, or
subpopulations defined by other common biomarkers, are plated on ultra lowattachment surfaces in serum-free medium supplemented with growth factors.
Cells that possess a stem cell-like phenotype will proliferate and form threedimensional, spherical colonies in suspension called tumorspheres. Cells that
lack a stem cell-like phenotype will quickly die from anoikis [26]. It is believed
that three-dimensional cell culture systems, such as mammosphere/
tumorsphere culture, serve as a more representative model of the in vivo cancer
environment than two-dimensional monolayer culture [27]. Furthermore, there
is a known association between the ability of breast cancer cells to form
tumorsphere in vitro and the in vivo tumorigenicity of tumorsphere-derived cells.
In one such study, Grimshaw et al. isolated metastatic cells from pleural effusions
of breast cancer patients, and subsequently placed them in tumorsphere culture.
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They then dissociated the tumorspheres and injected the tumorsphere-derived
cells into SCID mice. They found that cells that formed the largest tumorspheres
in vitro were also the most tumorigenic when xenografted into
immunocompromised mice [28,29].
Indeed, it is well known that tumorigenicity and differentiation ability can
be assessed by injecting isolated BCSCs subcutaneously in the mammary fat pad
of immunocompromised mice and observing the formation of primary tumors
containing both a BCSC population and a differentiated multi-lineage
population. The highly tumorigenic CD24-/CD44+ phenotype of BCSCs was
revealed in xenograft experiments conducted by the Wicha Laboratory at the
University of Michigan, where they showed that as few as twenty cells with
BCSC markers were required to generate primary heterogeneous tumors,
whereas anywhere from tens of thousands up to one million non-BCSC cells
were needed to generate primary tumors [14, 15].
The MCF7 Cell Line and the MCF10A/AT1 /CA1a
Breast Cancer Progression Model
The MCF7 cell line is one of the most widely used model systems in breast
cancer research. It originated from a pleural effusion of a 69-year-old Caucasian
woman. These cells have a luminal epithelial mammary gland phenotype, and
represent a luminal A tumor subtype. It is a mildly invasive breast ductal
carcinoma, and has an ER+/PR+/-/HER2- immunoprofile. This cell line has been
used widely for over forty years, and there has been extensive research done on
5

its molecular profile, invasion, migration and proliferation characteristics, and its
involvement in lymphangiogenesis and angiogenesis [30,31]. More recently, it
has been shown that that MCF7 cells have the ability to form tumorspheres when
cultured in serum-free medium in non-adherent conditions. [32]
The MCF10A breast cancer progression model consists of three cell lines:
MCF10A, MCF10AT1, and MCF10CA1a. The MCF10A cells are non-malignant
breast cells, derived from a patient with benign fibrocystic disease, that were
spontaneously immortalized. These cells are not capable of forming tumors [33].
MCF10A cells were transfected with constitutively active H-Ras to form the premalignant MCF10AT1 cell line, which is able to form tumors in xenograft
experiments with a 25% incidence [34]. MCF10AT1 cells were then
subcutaneously injected into mice and allowed to metastasize in order to form
the oncogenic MCF10ACA1a cell line, which contains a PIK3CA H1047R
activating mutation. These cells always result in tumor formation when injected
subcutaneously into immunocompromised mice [35]. This model system is
widely used to study breast cancer progression.
The RUNX Family of Proteins
The RUNX (runt-related transcription factor) family of proteins is a group
of evolutionarily conserved transcription factors that are involved in the
regulation of developmental processes. Mammals have three RUNX genes:
RUNX1, RUNX2 and RUNX3, and their expression and function vary based on
tissue type. RUNX genes are involved in many major pathways associated with
6

development, such as WNT3, Notch5, transforming growth factor-β (TGFβ ),
YAP1, and Indian hedgehog4. All three of the RUNX genes in mammals are
regulated by dual promoters, which are activated at different times during
development to create distinct RUNX isoforms. Isoforms of the RUNX genes,
which have distinctive properties, are also formed via alternative splicing events.
The Runt domain, a highly conserved DNA-binding domain that contains both
activation and inhibitory domains, is present in each of the RUNX proteins, and
it binds to CBFβ in order to stabilize the interaction of RUNX with the DNA. The
RUNX proteins are not strong transcriptional regulators by themselves, but their
interactions with other proteins, such as such as H3K4 methyltransferase mixedlineage leukaemia (MLL ), histone deacetylases (HDACs), and Polycomb
repressive complex 1 (PRC1), enhances their transcriptional activity [36-38].
The RUNX Genes and Cancer
Mutations in the RUNX genes are associated with a variety of cancers.
Mutations in RUNX1, also known as acute myeloid leukemia 1 protein (AML1),
play a significant role in leukemogenesis. RUNX2 is involved in bone
development and differentiation. It is a factor specific to the bone lineage, and it
is known to play a role in osteosarcoma. Elevated levels of RUNX2 are
associated with bone-metastatic breast and prostate cancer, whereas inactivation
of RUNX3 is a hallmark of many solid tumors [39–42]. The role that the RUNX
genes play in the development of cancer was greatly elucidated when it was
discovered that they are MYC-collaborating genes. All of the RUNX genes were
7

identified as viral insertional targets via proviral insertional mutagenesis
experiments in mice genetically engineered to exhibit MYC-overexpression in Tlymphocytes (CD2–Myc transgenic mice). It has also been shown that viralinduced overexpression of RUNX proteins can result in aggressive T-cell
lymphomas, and retroviral insertional mutation screens in Arf-knockout mice
have revealed a link between RUNX and p53 in both lymphomagenesis and
leukaemogenesis. [43-46]. Previous work from our lab using the MMTV-PyMT
transgenic mouse model of breast cancer confirmed that RUNX1 is associated
with breast cancer progression, and depletion of RUNX1 resulted in the
inhibition of breast cancer invasion and migration. In this study, high levels of
RUNX1 expression were found in MMTV-derived tumor cells, as well as in lungmetastatic legions of MMTV-PyMT mice. The ultimate conclusion drawn from
this work was that breast cancer progression and metastasis is strongly linked to
the dysregulation of RUNX1 in tumor epithelial cells [47]. Furthermore,
previous studies from our group have repeatedly shown that RUNX2 is involved
in breast cancer metastasis, predominantly to bone. [40,48,49]. Lastly, RUNX1
has been shown to be necessary for the development of mammary stem cells [50],
which lead us to speculate about its role in breast cancer stem cells, and recent
work done by our group has revealed that RUNX1 can function as a tumor
suppressor by inhibiting the EMT process and promoting the maintenance of the
epithelial phenotype [51].

8

CHAPTER 2: INVESTIGATING THE ROLE OF RUNX1
IN MCF7 BREAST CANCER STEM CELLS
Summary
The focus of this chapter is an analysis of a putative breast cancer stem cell
population within a well-known and extensively researched model system of
luminal breast cancer. It was hypothesized that since RUNX1 is known to have
tumor suppressor activity, and is also known to be involved in the development
of normal mammary stem cells, that depletion of the RUNX1 gene in MCF7 cells
would promote the breast cancer stem cell phenotype. An experimental
technique, the tumorsphere assay, was established for the first time in our
laboratory in order to investigate this hypothesis. In this body of work, we show
successful generation of tumorspheres, from the MCF7 cell line, that have
increased expression of genes known to be associated with the breast cancer stem
cell phenotype. We also show that when RUNX1 is depleted in this model
system by an shRNA approach, tumorsphere formation, an indicator of
tumorigenic potential, is increased; this outcome lends support to the role of
RUNX1 as a tumor suppressor.

Introduction
Tumorspheres are single cell-derived, three-dimensional spherical
colonies that grow in suspension when seeded into serum-free medium in ultra
low-attachment plates. Tumorsphere culture is an established method used to
9

enrich for BCSCs, which is evidenced by the fact that tumorsphere forming
ability of breast cancer cells in vitro correlates with the ability of tumorsphere
cells to form tumors in immunocompromised mice in vivo [28,29]. Additionally,
it is known that RUNX1 is involved in the development of normal mammary
stem cells [50], and previous work by our group and others has shown that
RUNX1 is involved in breast cancer progression [47]. Taken together, this
evidence led us to hypothesize that RUNX1 may be involved in the
establishment or maintenance of the BCSC population. In the experiments
outlined in this chapter, we set out to utilize tumorsphere culture of the MCF7
cell line, a well known, established cell line capable of tumorsphere formation
[30-32], as a means to enrich for BCSCs in order to begin investigating the
putative role of RUNX1 in the BSCS phenotype.

Materials and Methods
Cell Culture
MCF7 cells were cultured in 100 mm plates in Dulbecco’s Modified Eagle
Medium/Ham’s F-12 50/50 (Thermo Fisher Scientific, Waltham, MA, USA)
supplemented with 10% (v/v) fetal bovine serum (FBS) (Atlanta Biologicals,
Flowery Branch, GA, USA) and 1% (v/v) 50 IU/ml penicillin/50 µg/ml
streptomycin (Life Technologies, Carlsbad, CA, USA). Cells were passaged
every three to four days with 0.05% trypsin-EDTA, and media was replenished
every other day.
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Tumorsphere Culture
Adherent MCF7 cells were grown to 70 – 80% confluence and
enzymatically dissociated into a single-cell suspension with 0.05% trypsin-EDTA.
For tumorsphere formation assays, single cells were seeded into 6-well ultra-low
attachment plates (Corning, Corning, NY, USA) at a density of either 8,000 or
16,000 cells per well and maintained in Mammocult Medium (STEMCELL
Technologies, Vancouver, British Columbia, Canada) for four to five days. For
qRT-PCR analysis, cells were seeded at a density of 1 x106 cells per plate in 100
mm Petri dishes, for the same duration of time, in order to obtain enough
material for analysis. Tumorsphere formation efficiency (TFE) was calculated by
dividing the number of tumorspheres formed by the number of single cells
seeded, expressed as a percentage. Tumorspheres were manually counted under
100X magnification using an inverted phase-contrast microscope (Leica
Microsystems, Wetzlar, DE).
Quantitative Real-Time PCR
Adherent MCF7 cell cultures that were approximately 70-80% confluent
and Day 4-5 tumorsphere cultures were collected in Trizol (Life Technologies).
RNA was isolated using the miRNeasy Mini Kit (Qiagen, Germantown, MD,
USA). cDNA was synthesized using the SuperScript III First-Strand Synthesis
System for RT-PCR (Life Technologies) and subsequently diluted at a 1:15 ratio
prior to performing quantitative real-time PCR using SYBR Green PCR Master
Mix (Applied Biosystems Foster City, CA, USA).
11

Statistical Analysis
Tumorsphere formation efficiency assays were repeated at least three
times. The differences in mean values among groups were calculated, and TFE is
expressed as the mean ± SEM. qRT-PCR analyses were conducted on two
biological replicates.

Results
MCF7 Tumorsphere Assay
When adherent breast cancer cells are placed into tumorsphere culture
conditions in ultra-low attachment plates, these cells are prevented from
attaching to a substrate and are forced to grow in suspension. In such
conditions, the vast majority of cells die as a result of anoikis, while those that
have stem-like properties are able to replicate and form three-dimensional
spheroids. The most important aspect of tumorsphere culture is the density, and
this must be properly optimized in order to generate robust tumorsphere
cultures. If the cultures are seeded at too high of a density, the tumorspheres
will begin to fuse together, oftentimes so much so that all of the spheroids in a
given culture well or plate will fuse into one continuous string-like structure that
quickly becomes necrotic. In these experiments, tumorsphere cultures were
successfully harvested for qRT-PCR analysis. Photomicrographs were taken
every 24 hours for the duration of culture. Tumorspheres at Day 4 measured
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between 100 – 200 μm in diameter. Images shown are representative of at least
three biological replicates (Figure 1).
Tumorspheres began to be observable in culture at Day 1 when they were
typically between 20 – 50 μm in diameter. During both Day 1 and Day 2 of
culture, dying cells, or “ghost cells”, were observed attached to the forming
spheroids. These are the cells that lack stem-like properties and are undergoing
anoikis. Once the cultures reach Day 3 and Day 4, “ghost cells” were almost nonexistent and the tumorspheres exhibited a smooth surface morphology. It is
important to carefully determine beforehand the day that cultures reach
maturity, for this is when the tumorspheres need to be counted for TFE analysis.
The appropriate time to conduct the TFE assay is before the majority of the
tumorspheres in culture begin to exhibit dark, necrotic cores. Once this takes
place, the tumorspheres will continue to grow in size for several days; however,
the necrosis begins to consume the entirety of the spheroids. If the cultures are
allowed to go beyond this point, the spheroids will eventually begin to break
apart until the point where there are no observable live cells in the culture.
Through optimization, it was determined that the point of maturity for MCF7
tumorsphere culture was typically between Day 4 and Day 5.
Gene Expression Analysis of Adherent MCF7 Cells vs. 3-D Tumorsphere
Culture
Gene expression analysis by qRT-PCR was performed on adherent MCF7
cells as well as whole tumorspheres that were harvested on Day 4, and results
13

were analyzed using GAPDH as a control (Figure 2). Tumorsphere-derived cells
showed increased expression of RUNX1 (p = 0.043), RUNX2 (p = 0.044), Oct4 (p
= 0.036), Nanog (p = 0.0021), Sox2 (p = 0.0031) and Vimentin (p = 0.024)
compared to adherent cells. A very slight increase in CD44 and E-cadherin
expression was also observed in tumorspheres compared to adherent cells,
though this was not statistically significant, and there was no observable
difference in CD24 expression levels between tumorspheres and adherent cells.
This gene expression analysis was performed on two biological replicates. Gene
expression analysis of RUNX1 and RUNX2 levels was performed because the
aim of this study was to gain insight into whether or not altered levels of these
transcription factors are associated with the cancer stem cell phenotype. Oct4,
Nanog and Sox2 were examined because these are known markers of
pluripotency and stemness. Vimentin and E-cadherin were chosen because they
are known markers of the epithelial to mesenchymal transition (EMT), and
altered expression of EMT markers is often associated with the cancer stem cell
phenotype. CD24 and CD44 were examined because one known phenotype
associated with breast cancer stem cells is CD24low/-/CD44+, however significant
differences in these markers were not observed in adherent MCF7 cells
compared to whole tumorspheres. The CD24low/- fraction is a mixed population
of cells containing low or no CD24 expression as determined by FACS analysis.
We hypothesized that since BSCSs with this aggressive BCSC phenotype are
known to represent only a very small fraction of total breast cancer cells, this
14

CD24low/-/CD44+ phenotype was not observable when examining whole
tumorspheres that were not FACS sorted for these markers.
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Figure 1. MCF7 Tumorsphere Assay
MCF7 tumorsphere cultures were successfully established and maintained in
culture for a period of four days. Representative images are shown at 100X and
200X magnification. Tumorspheres at Day 4 measured between 100 – 200 µm.
Images shown are representative of at least three biological replicates
16

Figure 2. Gene Expression Analysis of Adherent MCF7 cells vs. MCF7
Tumorspheres.
MCF7 tumorsphere cells exhibited significantly increased expression of RUNX1,
RUNX2, and the pluripotency markers Oct4, Nanog and Sox2, as well as
decreased expression of Vimentin, compared to adherent cells. Differences in
CD24, CD44 and E-Cadherin expression levels were not significant. Error bars
represent mean ± SEM. P-values are shown where differences in expression
levels were significant. The expression differences in CD24, CD44 and ECadherin were not statistically significant.
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Tumorsphere Forming Efficiency of RUNX1-Depleted MCF7 Cells
To gain further insight into whether or not RUNX1 plays a role in the
breast cancer stem cell phenotype, we used a RUNX1-knockdown MCF7 cell line
previously created in our lab by Deli Hong [51]. We compared the tumorsphere
forming efficiency (TFE) across MCF7 parental cells, two shRNA knockdown
MCF7 stable cell lines representing two different shRNA constructs (C1 and C4),
as well as a non-silencing shRNA control (NS) (Figure 3). TFE values were as
follows: Parental = 1.25 ± 0.05% SEM, NS control = 1.17 ± 0.04% SEM, shRUNX1
C1 = 1.85 ± 0.03% SEM, and shRUNX1 C4 = 2.12 ± 0.05% SEM. These results
show that knockdown of RUNX1 in MCF7 cells resulted in increased
tumorsphere-forming ability compared to the non-silencing control. This
indicated that shRUNX1-depleted MCF7 cells have increased tumorigenic
potential, lending support to the notion that RUNX1 has tumor suppressor
activity, and providing evidence that knockdown of RUNX1 may promote
stemness in MCF7 cells.
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Figure 3. Analysis of Tumorsphere Forming Efficiency in MCF7 Parental Cells vs.
RUNX1 Knockdown.
shRUNX1 MCF7 cells exhibited an approximately 2-fold greater tumorsphere
forming ability compared with the non-silencing control. Results shown are
representative of three biological replicates.
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Discussion
These experiments represented our first investigations into the cancer
stem cell phenotype, as we set out to establish breast cancer stem cell research
protocols. Through lengthy optimization and troubleshooting, we were able to
successfully establish tumorsphere cultures from the MCF7 cell line. We showed
that tumorspheres, a known measure of tumorigenic potential and cancer
stemness, created from this model system express genes shown to be essential for
pluripotency and known to be associated with the breast cancer stem cell
phenotype. Our results also showed that tumorsphere-derived breast cancer
stem cells exhibited increased expression of RUNX1 and RUNX2 compared to
adherent cells. Furthermore, our results revealed that both shRUNX1 MCF7 cell
lines exhibited increased tumorsphere-forming ability (~2-fold) compared with
the non-silencing control. This indicated that knockdown of RUNX1 increased
tumorigenic potential; lending support to the notion that RUNX1 exhibits tumor
suppressor activity.
Interestingly, although loss of RUNX1 increased tumorsphere forming
efficiency, the tumorsphere population as a whole exhibited higher RUNX1
expression levels than adherent MCF7 cells. This observation suggested that
perhaps there is a subpopulation of cells within tumorspheres that express high
levels of RUNX1 that may potentially represent breast cancer stem cells with
significantly enhanced tumorigenic potential.
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The initial rationale for this investigation strategy was to utilize
tumorsphere culture as a means of enriching a breast cancer stem cell population
large enough to conduct downstream analyses, since the CD24-/CD44+ fraction
in our MCF7 cell line was incredibly scarce (~ 0.5 – 1.0% of cells). This method
proved to be technically unfeasible and prohibitively expensive, and thus this
line of investigation was cut short. As a result, some experiments did not include
a minimum of three biological replicates. We decided to move on to a different
model system, which provided a much larger CD24-/CD44+ population to work
with, discussed in the next chapter.
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CHAPTER 3: INVESTIGATING THE ROLE OF RUNX1 AND RUNX2 IN THE
MAINTENANCE OF THE CANCER STEM CELL PHENOTYPE
IN A BREAST CANCER PROGRESSION MODEL
Summary
The focus of this chapter is the identification and analysis of a putative
breast cancer stem cell population within a known model system of breast cancer
progression. We were able to identify, isolate and investigate a CD24low/-/CD44+
breast cancer stem cell subpopulation within the pre-malignant, tumorigenic
MCF10AT1 cell line of this progression model. We showed that this BCSC
subpopulation has decreased levels of RUNX1 expression and increased levels of
RUNX2 expression compared to the non-BCSC population, lending further
support to the putative role of RUNX1 as a tumor suppressor. Given the fact that
elevated levels of RUNX2 are associated with some metastatic breast cancers,
and the fact that breast cancer stem cells are known to have increased metastatic
potential, we hypothesized that depletion of RUNX2 by an shRNA approach
would suppress the breast cancer stem cell phenotype. Our results provided
preliminary evidence that depleting RUNX2 decreased the breast cancer stem
cell population in this model system of breast cancer progression.

Introduction
The MCF10A model consists of three cell lines that together represent a
complete progression system from normal, but immortalized, breast epithelial
cells to fully metastatic breast cancer cells. MCF10A cells were derived from
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benign breast tissue of a female patient with fibrocystic disease. These cells were
subsequently transformed via transfection with T24 Ha-ras to form the
premalignant MCF10AT1 cell line. MCF10AT1 cells were then subcutaneously
injected into SCID mice and allowed to metastasize in order to generate the
metastatic MCF10CA1a cell line [34,35].
It has previously been established by our group that RUNX1 and RUNX2
are intimately involved in breast cancer progression and metastasis [47-49].
Furthermore, it is known that BCSCs are a highly aggressive and metastatic
subpopulation of tumor cells thought to be responsible for cancer onset,
metastasis and recurrence following remission [14,15]. Based on the outcomes of
the experiments outlined in Chapter 1, we needed to find a way to obtain a
greater number of BCSCs in order to further our investigations. Since it is known
that human BCSCs can be identified by the CD24low/-/CD44+ phenotype [16], and
since our preliminary FACS analyses of this model system indicated that there
may be a significant CD24low/-/CD44+ subpopulation within the MCF10AT1 cell
line, we chose this model in order to obtain a more robust CD24low/-/CD44+
BCSC population with which to further investigate the putative roles of RUNX1
and RUNX2 in the BCSC phenotype.
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Materials and Methods
Cell Culture
MCF10A and MCF10AT1 cells were cultured in 100 and 150 mm plates in
Dulbecco’s Modified Eagle Medium/Ham’s F-12 50/50 (Thermo Fisher
Scientific) supplemented with 5% (v/v) horse serum (Thermo Fisher Scientific),
100 ng/ml cholera toxin (Sigma Aldrich, St. Louis, MO), 10 µg/ml human insulin
(Sigma Aldrich), 20 ng/ml recombinant hEGF (Peprotech, Rocky Hill, NJ), 0.5
µg/ml hydrocortisone (Sigma Aldrich), and 1% (v/v) 50 IU/ml penicillin/50
µg/ml streptomycin (Life Technologies). MCF10CA1a cells were cultured in 100
and 150 mm plates in Dulbecco’s Modified Eagle Medium/Ham’s F-12 50/50
(Thermo Fisher Scientific) supplemented with 5% (v/v) horse serum (Thermo
Fisher Scientific) and 1% (v/v) 50 IU/ml penicillin/50 µg/ml streptomycin (Life
Technologies). Cells were passaged every three to five days with 0.05% trypsinEDTA, and media was replenished every other day. The shRUNX2 cell lines
were created by Alexandra Ojemann, a Master’s student in the Stein-Lian
Laboratory.
Mammosphere and Tumorsphere Culture
Adherent MCF10A, MCF10AT1 and MCF10CA1a cells were grown to 70 –
80% confluence and enzymatically dissociated into single-cell suspensions with
0.05% trypsin-EDTA. Mammosphere are three-dimensional spherical colonies
formed from non-transformed mammary cells, while tumorspheres are threedimensional spherical colonies formed from transformed mammary cells. For
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mammosphere (MCF10A) and tumorsphere (MCF10AT1, MCF10CA1a)
formation assays, single cells were seeded into 24-well ultra-low attachment
plates (Corning) at a density of either 1,000 or 2,000 cells per well and maintained
in Mammocult Medium (STEMCELL Technologies) for five to seven days.
Tumorsphere formation efficiency (TFE) was calculated by dividing the number
of tumorspheres formed by the number of single cells seeded, expressed as a
percentage. Tumorspheres were manually counted under 100X magnification
using an inverted phase-contrast microscope (Leica Microsystems).
CD24/CD44 Flow Cytometry
Adherent monolayer cultures of MCF10A, MCF10AT1 and MCF10CA1a
cells were grown to 70 – 80% confluence and gently dissociated with Accutase
(MP Biomedicals, Santa Ana, CA, USA). Culture vessels with Accutase were
placed at 37° C and checked every 60 seconds to minimize incubation time with
the dissociation agent in order to preserve the integrity of the cell surface
markers. The Accutase was immediately neutralized with fetal bovine serum
(Atlanta Biologicals) and the cells were subsequently washed with 1x phosphate
buffered saline (PBS) at a concentration of 10 mM PO43-, 137 mM NaCl, and 2.7
mM KCl . Cells were then quickly counted on a Countess automated cell counter
(Invitrogen/Thermo Fisher Scientific) and 1x106 cells were re-suspended in 100
µl 1x PBS/1%FBS containing 0.64 µg of PE/Cy7 anti-human CD24 (Biolegend,
San Diego, CA, USA, cat. # 311120) and 5µl of APC mouse anti-human CD44 (BD
Biosciences, San Jose, CA, USA, cat. # 559942). Equivalent amounts of matched
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isotype controls, PE/Cy7 Mouse IgG2a, κ (Biolegend, cat. # 400232) and APC
mouse IgG2b κ (BD Biosciences, cat. # 555745), were used. Cells were incubated
with antibodies for thirty minutes at room temperature, washed twice with
1xPBS/1%FBS, re-suspended in 400 µl 1xPBS/1%FBS and passed through a 40
µm Falcon cell strainer (Thermo Fisher Scientific) in order to obtain a single-cell
suspension. Cells were then either analyzed on a BD LSRII flow cytometer (BD
Biosciences) or analyzed and sorted into CD24low/-/CD44+ breast cancer stem cell
(BCSC) and CD24+/CD44+ non-BCSC fractions on a BD FACS AriaIII (BD
Biosciences) high-speed cell sorter. Analysis of flow cytometry data was
performed on FlowJo software version 10.0.8rl
Quantitative Real-Time PCR
CD24low/-/CD44+ BCSC and CD24+/CD44+ non-BCSC fractions were
isolated via FACS and subsequently placed in Trizol (Life Technologies). RNA
was isolated using the miRNeasy Mini Kit (Qiagen). cDNA was synthesized
using the SuperScript III First-Strand Synthesis System for RT-PCR (Life
Technologies) and subsequently diluted at a 1:15 ratio prior to performing
quantitative real-time PCR using SYBR Green PCR Master Mix (Applied
Biosystems).
Western Blotting
Sorted cells were lysed with radioimmunoprecipitation assay buffer
(RIPA) consisting of 150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS) and 50 mM Tris (pH 8.0), as
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well as 2X SDS sample buffer consisting of 1 M Tris (pH 6.8), 50% glycerol, 10%
SDS, 0.5% bromophenol blue, 0.5% β-mercaptoethanol, 5 μM MG132 proteasome
inhibitor (EMD Millipore San Diego, CA, USA), and cOmplete EDTA-free
protease inhibitor cocktail tablets (1 tablet per 10 ml) (Roche Diagnostics,
Indianapolis, IN, USA). Cell lysates were fractionated in an 8.5% polyacrylamide
gel and immunoblotted. Gels were wet-transferred to PVDF membranes (EMD
Millipore) using a Bio-Rad transfer apparatus (Bio-Rad Laboratories, Hercules,
CA, USA). Membranes were blocked with 5% Blotting Grade Blocker Non-Fat
Dry Milk (Bio-Rad Laboratories) and primary antibody incubation was
performed overnight at 4°C using the following primary antibodies: rabbit
monoclonal RUNX1 (Cell Signaling Technology, Danvers, MA, USA: #4336,
1:1000); rabbit monoclonal RUNX2 (Cell Signaling Technology #12556, 1:1000);
rabbit monoclonal Zeb1/TCF8 (Cell Signaling Technology #3396, 1:1000); mouse
monoclonal Vimentin (Santa-Cruz Biotechnology, Santa Cruz, CA, USA: sc-6260,
1:1000); mouse monoclonal E-cadherin (Santa Cruz Biotechnology sc21791,
1:1000); mouse monoclonal β-Actin (Cell Signaling Technology #3700, 1:1000).
HRP-conjugated secondary antibodies (Santa Cruz Biotechnology) were used for
immunodetection. Blots were developed using Clarity Western ECL Substrate
(Bio-Rad Laboratories) and subsequently imaged on the Chemidoc XRS+
imaging system (Bio-Rad Laboratories).
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Statistical Analysis
Tumorsphere formation efficiency assays were repeated at least three
times. The differences in mean values among groups were calculated, and TFE is
expressed as the mean ± SEM. qRT-PCR analyses were repeated three times.
GAPDH was used as a control. Relative mRNA levels were analyzed using a
student's t-test. P-values less than 0.05 were considered statistically significant
(*P < 0.05, **P < 0.01, ****P < 0.0001).

Results
Identification and Isolation of Breast Cancer Stem Cells
We set out to determine if we could identify and isolate CD24low/-/CD44+
BCSC populations in the MCF10A progression model. Indeed, our results
showed that we were able to identify a CD24low/-/CD44+ subpopulation in the
MCF10AT1 cell line. Both the BCSC subpopulation and the non-BCSC
CD24+/CD44+ population were isolated by FACS. The BCSC fraction
represented, on average, between 17 – 23% of total live cells gated. Matched
isotype controls and single-stained control samples were use to establish gating
parameters, and the gating strategy was specifically designed to allow for
maximum separation between the BCSC and non-BCSC populations with respect
to CD24 expression: one gate was centered around the densest region of the
CD24low/-/CD44+ subpopulation and the other gate was centered around the
densest region of the CD24+/CD44+ population. (Figure 4).
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Figure 4. FACS Gating Strategy for MCF10AT1 CD24low/-/CD44+ BCSC and
CD24+/CD44+ non-BCSC Populations.
A distinct CD24low/-/CD44+ BCSC subpopulation was discovered in the
MCF10AT1 cells. Gates were used to isolate non-BCSCs from BCSCs. The BCSC
subpopulation ranged from ~ 17 – 23% of the total cell population.
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MCF10A/AT1/CA1a Mammosphere/Tumorsphere Assay
Next, we investigated whether or not all cell lines in this system were
capable of forming mammospheres and tumorspheres (see Materials and
Methods). Briefly, adherent cells were enzymatically detached and single-cell
suspensions were created. Cells were seeded at a density of either 1,000 or 2,000
cells per well in 24-well ultra low-attachments plates and maintained in serumfree culture medium for a period of five to seven days. Our results showed that
MCF10A mammosphere as well as MCF10AT1 and MCF10CA1a tumorsphere
cultures were successfully established and maintained in culture for a period of
five days. Each cell line was cultured in four separate wells in order to have four
technical replicates. Photomicrographs were taken every twenty-four hours for
the duration of culture. A minimum of four images was taken for each well in
order to create an archive of the most representative images possible. MCF10A
mammospheres measured ≤ 100 μm in size, while MCF10AT1 and MCF10CA1a
tumorspheres measured between 100 - 400 μm in size. Tumorspheres showed a
drastically larger morphology compared to mammospheres. MCF10AT1
tumorspheres exhibited a more uneven and rough surface morphology than
MCF10CA1a tumorspheres, which exhibited a smooth surface morphology
(Figure 5). As we expected, due to the fact that cancer cells divide
uncontrollably, the tumorspheres formed by the cancerous cell lines were
markedly larger than the mammospheres formed by the MCF10A cells. The
unique morphologies associated with the three-dimensional spheroids formed
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by each cell line were reproducibly observed in upward of twenty biological
replicates.
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Figure 5. MCF10A, MCF10AT1 and MCF10CA1a Mammosphere/Tumorsphere
Assays.
MCF10A (mammosphere), MCF10AT1 and MCF10CA1a (tumorsphere) cultures
were successfully established and maintained in culture for a period of 5 days.
Tumorspheres exhibited a larger morphology compared to mammospheres, and
distinct morphological differences between spheroids from the three different
cell lines were observed. Images shown are representative of at least three
biological replicates, and are shown at 100X magnification.
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Tumorsphere Forming Capacity of MCF10AT1 Subpopulations
In order to gain further insight into the true tumorsphere forming ability
of BCSCs versus non-BCSCs from MCF10AT1 cell cultures, we performed threedimensional tumorsphere assays with FACS-sorted populations. Tumorsphere
cultures from CD24low/-/CD44+ BCSCs and CD24+/CD44+ non-BCSCs were
successfully established and maintained in culture for a period of seven days.
Photomicrographs were taken every twenty-four hours for the duration of
culture. Tumorspheres formed from CD24+/CD44+ non-BCSCs measured ≤ 100
μm in size, while CD24low/-/CD44+ BCSC tumorspheres measured in excess of
400 μm in size over the course of seven days (Figure 6). In these experiments,
there were extreme size and morphological differences in spheroids formed by
BCSCs compared to non-BCSCs, and these observations were consistent
throughout multiple biological replicates.
In order to quantify the tumorsphere forming ability of both cancer stem
cell and non-cancer stem cell populations, we calculated the tumorsphere
forming efficiency (TFE) of each population. TFE was compared between
MCF10AT1 CD24low/-/CD44+ BCSCs and the CD24+/CD44+ non-BCSC
population. TFE values were as follows: BCSCs = 3.63 ± 0.15% SEM, and nonBCSCs = 1.4 ± 0.15% SEM (Figure 7). As expected, the cancer stem cell
subpopulation had a much higher TFE than the non-stem cell population and the
tumorspheres formed by the BCSCs were significantly larger.
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A

B

Figure 6. MCF10AT1 CD24low/-/CD44+ BCSC and CD24+/CD44+ non-BCSC
Tumorsphere Assays.
(A) Tumorspheres formed from FACS-isolated BCSCs exhibited a vastly different
morphology than those formed from (B) FACS-isolated non-BCSCs. Images
shown are representative of at least three biological replicates, and are shown at
100X magnification.
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Figure 7. Analysis of Tumorsphere Forming Efficiency in MCF10AT1 CD24low//CD44+ BCSC and CD24+/CD44+ non-BCSC Tumorsphere Assays.
MCF10AT1 CD24low/-/CD44+ BCSCs exhibited increased tumorsphere forming
efficiency (p = 0.0019) compared to the CD24+/CD44+ non-BCSC population.
Results are representative of three biological replicates. n = 3.
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RNA and Protein Expression Analysis of MCF10AT1 CD24low/-/CD44+ BCSCs
vs. CD24+/CD44+ non-BCSCs
We next examined expression of several genes, including several stem cell
markers, in the CD24low/-/CD44+ breast cancer stem cell population of
MCF10AT1 cells compared to the CD24+/CD44+ non-breast cancer stem cell
population. The CD24low/-/CD44+ breast cancer stem cell population of
MCF10AT1 cells exhibited a statistically significant increase in expression of
RUNX2 (p = 0.0068), Vimentin (p = 0.0026), Nanog (p = 0.0034), Zeb1 (p =
0.0022), and Zeb1 lncRNA (p = 0.0063) compared to non-BCSCs, and showed a
statistically significant decrease in expression of RUNX1 (p = 0.041), Oct 4 (p =
0.013) and CD24 (p < 0.0001) compared to non-BCSCs (Figure 8). CD44 RNA
expression was elevated in BCSCs, though this difference was not statistically
significant (Figure 8). RUNX1 decreased slightly (p = 0.041) and RUNX2
increased slightly (p = 0.0068) within the CD24low/-/CD44+ BCSCs compared to
the non-BCSCs. The changes in RUNX1 and RUNX2 expression appeared to
decrease and increase, respectively, with CD24 expression. The pluripotency
marker Nanog increased in expression (p = 0.0034) in the BCSC population
compared to non-BCSCs, and expression of Nanog increased with decreased
CD24 expression. Similarly, expression of Zeb1 and Zeb1 lncRNA also increased
with decreased CD24 expression.
We observed a reciprocal relationship between RUNX1 and RUNX2
expression in MCF10AT1 BCSCs. We know from our observations in the MCF7
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cell line that knockdown of RUNX1 can increase TFE and promote
tumorigenicity. Given our observation that expression of RUNX2 is increased in
BCSCs, and considering the fact that RUNX2 is involved in metastatic cancer, we
hypothesized that RUNX2 is involved in promoting or maintaining stemness in
the BCSC population, and that knockdown of RUNX2 will decrease TFE in the
CD24low/-/CD44+ population. This hypothesis was tested in subsequent
experiments.
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Figure 8. Gene Expression Analysis of MCF10AT1 CD24low/-/CD44+ BCSCs vs.
CD24+/CD44+ non-BCSCs.
MCF10AT1 BCSCs exhibited significantly increased expression of RUNX2,
Vimentin, Nanog, Zeb1 and Zeb1 lncRNA compared to non-BCSCs, as well as
significantly decreased expression of RUNX1, Oct4 and CD24 compared to nonBCSCs. P-values are shown where expression differences were significant. The
difference in CD44 expression was not statistically significant.
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Consistent with results from RNA expression analysis, MCF10AT1 CD24low//CD44+ BCSCs exhibited a marked increase in RUNX2, Zeb1 and Vimentin
protein levels, and a decrease in RUNX1, E-Cadherin and CD24 protein levels
compared to non-BCSCs. β-actin was used as a loading control. Western blot
and protein quantification results are representative of one biological replicate,
and thus not statistically significant. However, others in our group have
replicated these experiments in triplicate and results are consistent with the data
shown (Figure 9).
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Figure 9. Western Blots and Protein Quantification of RUNX1, RUNX2, Zeb1,
Vimentin and CD24 in MCF10AT1 CD24low/-/CD44+ BCSCs vs. CD24+/CD44+
non-BCSCs.
BCSCs exhibited a marked increase in RUNX2, Zeb1 and Vimentin as well as a
decrease in RUNX1, E-Cadherin and CD24 compared to non-BCSCs as indicated
by Western blot and associated protein quantification.
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CD24/CD44 Flow Cytometric Analysis and Tumorsphere Forming Efficiency
of MCF10AT1 shRUNX2 Knockdown Cells
In order to test our hypothesis that knockdown of RUNX2 will decrease
the BCSC population, CD24/CD44 flow cytometry was performed on
MCF10AT1 parental, shRUNX2 knockdown, and empty vector control cells lines.
Results show that the distinct CD24low/-/CD44+ BCSC subpopulation observed in
the parental cells is decreased in shRUNX2 knockdown cells versus empty vector
control. According to FACS analysis, the CD24low/-/CD44+ subpopulation
represents ~ 24% of live-gated cells in the parental cell line, ~ 12% of live-gated
cells in the EV control, and ~ 4% of live-gated cells in the shRUNX2 cell line.
These results are representative of three biological replicates (Figure 10).
In order to gain further evidence in support of our hypothesis, we
examined the tumorsphere forming ability of MCF10AT1 shRUNX2 cells,
shRUNX2 empty vector control, and the MCF10AT1 parental cell line. The TFE
of shRUNX2 MCF10AT1 cells was 0.70 ± 0.12% SEM versus 1.53 ± 0.15% SEM for
the empty vector control and 1.83 ± 0.12% SEM for the parental cell line (Figure
11). These results support our hypothesis that knockdown of RUNX2 decreases
the BCSC subpopulation in MCF10AT1 cells.
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Figure 10. CD24/CD44 Flow Cytometry of MCF10AT1 shRUNX2 Knockdown
Cells vs. Parental and Empty Vector Control.
MCF10AT1 shRUNX2 knockdown cells showed a marked decrease in the
CD24low/-/CD44+ BCSC subpopulation vs. empty vector control and parental
cells. The CD24low/-/CD44+ subpopulation represents ~ 24% of live-gated cells in
the parental cell line, ~ 12% of live-gated cells in the EV control, and ~ 4% of livegated cells in the shRUNX2 cell line.
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Figure 11. Tumorsphere Assays and TFE Analysis of MCF10AT1 shRUNX2
Knockdown Cells vs. Parental and Empty Vector Control.
MCF10AT1 shRUNX2 knockdown cells exhibited decreased tumorsphere
forming efficiency compared to empty vector control and parental. Assay was
performed in triplicate, and images are shown at 100X magnification.
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Discussion
In order to obtain a robust CD24-/CD44+ breast cancer stem cell
population, we turned to the MCF10A/AT1/CA1a breast cancer progression
model system [30,31]. Initial flow cytometric analysis revealed a distinct
CD24low/-/CD44+ BCSC subpopulation within the pre-malignant, tumorigenic
MCF10AT1 cell line. This subpopulation exhibited decreased levels of RUNX1
and increased levels of RUNX2 compared to the non-BCSC population.
Expression levels of Vimentin, Nanog, Zeb1, and Zeb1 lncRNA were also
elevated in the BCSC population compared to the non-BCSC population, while
expression levels of Oct4 and CD24 were decreased in the BCSC population. We
also showed that knockdown of RUNX2 decreased tumorigenicity, as measured
by the tumorsphere formation assay. Taken together, these observations suggest
that a combination of low expression of RUNX1 and elevated expression of
RUNX2 may be involved in the maintenance or development of the breast cancer
stem cell phenotype.
The shRNA RUNX2 knockdown MCF10AT1 cell line was created by
Alexandra Ojemann, a Master’s student in the Stein-Lian Laboratory. However,
subsequent RNA-seq analysis indicated that this may not have been a complete
knockdown. As a result, the observations made here cannot be interpreted with
a high degree of certainty, and it would be appropriate to repeat these
experiments with a different set of shRUNX2 knockdown cell lines.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
Summary
The findings presented in this body of research provide evidence that
regulation of, or cellular pathways involved in the regulation of, RUNX1 and
RUNX2 may be important for the maintenance of the breast cancer stem cell
phenotype. We were able to show, in two different model systems, that low
expression levels of RUNX1 and elevated expression levels of RUNX2 are
present in CD24low/-/CD44+ breast cancer stem cells.
In Chapter 2, we show definitively that knockdown of RUNX1 enhances
tumorigenicity in breast cancer cells, as measured by tumorsphere formation
efficiency. In Chapter 3, our observations suggest that knockdown of RUNX2
depletes the CD24low/-/CD44+ breast cancer stem cell subpopulation and
represses tumorigenicity of breast cancer cells, as measured by the tumorsphere
formation assay.

Implications and Future Directions
The results presented in this thesis represent preliminary investigations
into the putative roles of RUNX1 and RUNX2 in maintenance of the breast cancer
stem cell phenotype. In order to lend more credence to these observations, the
work with the MCF7 cell line needs to be reproduced and expanded upon, and
the work done with the knockdown RUNX2 MCF10AT1 cells needs to be
repeated with newly created stable knockdown cell lines. There are several
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exciting implications put forth by this body of work that, if expanded upon, have
the potential to reveal significant insights into the putative roles of RUNX1 and
RUNX2 in regulating the breast cancer stem cell phenotype. This body of work
has, for the first time, effectively established three-dimensional cancer stem cell
culture protocols for our group. There is no doubt that, with time, our group
will expand upon these studies in order to glean further insights into the
mechanisms that govern stemness in breast cancer.
Using the mammosphere/ tumorsphere culture protocols for a variety of
breast cancer cell lines that have been developed through this work, there are
several avenues of investigation that we can now potentially pursue. It would be
very exciting to see if we can establish tumorsphere cultures from patient breast
cancer tissue samples, isolate and conduct analyses on the CD24low/-/CD44+
fraction, and compare the results to those obtained through these investigations.
A study such as this would enable us to gain further insight into the involvement
of RUNX1 and RUNX2 in regulating or maintaining the BCSC phenotype.
Furthermore, we now have a three-dimensional cell culture system designed to
enrich for BCSCs that can potentially be used for drug screening, toxicity testing,
and further knockdown experiments.
Given the fact that traditional cancer therapeutics are insufficient at
targeting breast cancer cells with stem cell-like properties, it is of paramount
importance that genes and regulatory molecules responsible for governing
stemness in breast cancer cells are identified so that novel therapies can be
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developed to target and eliminate this incredibly dangerous subpopulation of
cells. Indeed, it is widely accepted that breast cancer stem cells are a main
causative factor in the initial onset of cancer, and are thought to be responsible
for cancer recurrence following remission, as well as metastasis that ultimately
leads to death. Findings from this research lay a strong groundwork for future
investigations into cellular pathways that govern stemness in breast cancer cells.
Gene expression analyses performed here provide interesting starting points for
future investigation into genes that are potentially involved in maintaining the
breast cancer stem cell phenotype. It would also be very interesting to analyze
these BCSC populations at the epigenetic level in order to gain insight into
epigenetic regulatory mechanisms involved in governing the breast cancer stem
cell phenotype.
Since there still remains much debate over the consensus of populationdefining cell-surface markers, and taking into consideration the fact that there is
a general lack of cell-surface markers ascribed to them, it continues to be
extremely challenging to identify and isolate cancer stem cells (CSCs) from solid
tumors. As a result, functional assays are the techniques that are predominantly
used to assess the ability of CSCs, or prospective CSC populations, to generate
tumors via self-renewal, asymmetric division, and differentiation. Many of these
assays are extremely costly and time-consuming because they are based on the
formation of tumors in vivo following xenograft transplantations into
immunocompromised mice. Since the capability to form spheroids in vitro is an
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established method to identify CSC populations, spheroid formation assays
represent a relatively low-cost in vitro model with which to investigate the CSC
phenotype.
Three-dimensional cell culture systems are thought to better mimic the in
vivo cancer environment compared to traditional two-dimensional monolayer
systems. Some of the most popular three-dimensional cell culture systems for
studying breast cancer are tumorspheres and organoids, and tumorsphere
culture is specifically known to enrich for BCSCs. Future investigations in the
field utilizing these two systems will surely help to usher in the discovery of yet
to be identified cell-surface markers that will ultimately aid in the development
of therapeutics that can target the dangerous BCSC cell populations with
enhanced specificity [52-54]. In fact, several developments have occurred since
the writing of this manuscript that have served to advance the fields of breast
tumorsphere and organoid research. Dr. Hans Clever’s Laboratory has
developed a breast cancer organoid biobank consisting of over one hundred
organoid lines. Since these organoids are by definition patient-derived threedimensional cell culture systems, they are highly representative of their in vitro
breast tumor counterparts, and these models have been adapted for highthroughput screening [55]. The Clevers Lab has also developed organoid
systems for gastrointestinal cancers, which they’ve shown to be highly effective
models for drug screening. In these patient-derived gastrointestinal organoid
cultures, every time that a drug did not work in a patient’s organoids, it also did
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not work in the patient. Furthermore, in almost nine out ten cases when drugs
were first tested and shown to work in a patient’s organoids, the patient
exhibited a response to the drug [56]. Tumorspheres differ from organoids in
that they don’t recapitulate the original tissue hierarchy to the same extent,
however they are three-dimensional cell culture systems that better mimic the in
vivo environment than traditional two-dimensional monolayer systems, they are
more cost effective and less time-consuming, and tumorsphere cultures can also
be readily adapted for high-throughput screening.
It is clear that three-dimensional cell culture systems will play an
incredibly important role in the future of cancer research. The protocols
established via this body of research have laid the groundwork for our group to
further investigate the molecular mechanisms of breast cancer progression and
metastasis using three-dimensional tumorsphere culture. This body of work has
also provided invaluable insights into the involvement of RUNX1 and RUNX2 in
the maintenance of the BCSC phenotype; insights that can be expanded upon to
further our understanding of BCSC biology, aid in the discovery of novel BCSC
markers, and assist in investigations into the mechanisms of epigenetic
regulation and cell-specific nuclear architecture associated with the BCSC
phenotype.

49

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.

BIBLIOGRAPHY
Bruce WR & Van Der Gaag H. A quantitative assay for the number of
murine lymphoma cells capable of proliferation in vivo. Nature 199: 79–80
(1963).
Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells:
a primary cell culture assay. J Natl Cancer Inst 46: 411–422 (1971).
Sharpe B, Beresford M, Bowen R, et al. Searching for prostate cancer stem
cells: markers and methods. Stem Cell Rev. 9(5): 721-30 (2013).
Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective
identification of tumorigenic breast cancer cells. Proc Natl Acad Sci
USA 100: 3983–3988 (2003).
Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain
tumour initiating cells. Nature 432: 396–401 (2004).
O’Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable
of initiating tumour growth in immunodeficient mice. Nature 445: 106–110
(2007).
Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion
of human colon-cancer-initiating cells. Nature 445: 111–115 (2007).
Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating
human melanomas. Nature 451: 345–349 (2008).
Visvader JE & Lindeman GJ. Cancer stem cells in solid tumours:
accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755768 (2008).
Meacham CE & Morrison SJ. Tumour heterogeneity and cancer cell
plasticity. Nature 501: 328-337 (2013).
Girouard SD & Murphy GF. Melanoma stem cells: not rare, but well done
Laboratory Investigation 91: 647–664 (2011).
Zhao J. Cancer stem cells and chemoresistance: The smartest survives the
raid. Pharmacology & Therapeutics 160: 145-158 (2016).
Abdullah LN & Chow EKH. Mechanisms of chemoresistance in cancer
stem cells. Clinical and Translational Medicine 2: 3-3 (2013).
McDermott SP & Wicha MS. Targeting breast cancer stem cells. Molecular
oncology 4(5): 404-419 (2010).
Liu S & Wicha MS. Targeting breast cancer stem cells. Journal of clinical
oncology: official journal of the American Society of Clinical Oncology 28(25):
4006-4012 (2010).
Velasco-Velazquez MA, Homsi N, De La Fuente M, et al. Breast cancer
stem cells. The international journal of biochemistry & cell biology 44(4): 573577 (2012).
Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem
cells. Nature 414: 105–111 (2001).

50

18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.

Sun B, Chen M, Hawks CL, et al. The minimal set of genetic alterations
required for conversion of primary human fibroblasts to cancer cells in the
subrenal capsule assay. Neoplasia 7: 585–593 (2005).
Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed
progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442: 818–
822 (2006).
Clarke MF & Fuller M. Stem cells and cancer: two faces of eve. Cell 124:
1111–1115 (2006).
Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage
progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J
Med 351: 657–667 (2004).
Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or
reality? Nat Med 15: 1010–1012 (2009).
Scheel C & Weinberg RA. Cancer stem cells and epithelial–mesenchymal
transition: Concepts and molecular links. Seminars in Cancer Biology 22:
396-403 (2012).
Ly D, Forman D, Ferlay J, et al. An international comparison of male and
female breast cancer incidence rates. International journal of cancer. Journal
international du cancer 132(8): 1918-1926 (2013).
Liu Y, Nenutil R, Appleyard MV. Lack of correlation of stem
cell markers in breast cancer stem cells. Br J Cancer 110(8): 2063-71 (2014).
Saadin K & White IM. Breast cancer stem cell enrichment and isolation by
mammosphere culture and its potential diagnostic applications. Expert
review of molecular diagnostics 13(1): 49-60 (2013).
Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of
sphere-formation as an assay for stem cells. Cell Stem Cell 8: 486–98 (2011).
Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of
tumorigenic breast cancer cells with stem/progenitor cell properties.
Cancer Res 65: 5506–11 (2005).
Grimshaw MJ, Cooper L, Papazisis K, et al. Mammosphere culture of
metastatic breast cancer cells enriches for tumorigenic breast cancer cells.
Breast Cancer Res. 10: R52 (2008).
Comşa Ş, Cîmpean AM, Raica M. The Story of MCF-7 Breast Cancer Cell
Line: 40 years of Experience in Research. Anticancer Res 35(6): 3147-54
(2015).
Levenson AS & Jordan C. MCF-7: The First Hormone-responsive Breast
Cancer Cell Line. Cancer Research 57: 3071-307 (1997).
Iglesias JM, Beloqui I, Garcia-Garcia F, et al. Mammosphere Formation in
Breast Carcinoma Cell Lines Depends upon Expression of E-cadherin.
PLoS ONE 8(10): e77281 (2013).
Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization
of a spontaneously immortalized human breast epithelial cell line, MCF10. Cancer Res 50(18): 6075–86 (1990).
51

34.
35.
36.
37.
38.

39.
40.
41.
42.
43.

Dawson PJ, Wolman SR, Tait L, et al. MCF10AT: a model for the evolution
of cancer from proliferative breast disease. Am J Pathol 148(1): 313–19
(1996).
Santner SJ, Dawson PJ, Tait L, et al. Malignant MCF10CA1 cell lines
derived from premalignant human breast epithelial MCF10AT cells. Breast
Cancer Res Treat 65(2): 101–10 (2001).
Yu M, Mazor T, Huang H, et al. Direct recruitment of polycomb repressive
complex 1 to chromatin by core binding transcription factors. Mol. Cell 45:
330–343 (2012).
Guo H. & Friedman AD. Phosphorylation of RUNX1 by cyclin-dependent
kinase reduces direct interaction with HDAC1 and HDAC3. J. Biol. Chem.
286: 208–215 (2011).
Westendorf JJ, Zaidi SK, Cascino JE, et al. Runx2 (Cbfa1, AML-3) interacts
with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter.
Mol. Cell. Biol. 22: 7982–7992 (2002).
Ito Y, Bae SC, Chuang, LSH. The RUNX family: developmental regulators
in cancer. Nat Rev Cancer 15: 81-95 (2015).
Mangan JK & Speck NA. RUNX1 mutations in clonal myeloid disorders:
from conventional cytogenetics to next generation sequencing, a story 40
years in the making. Crit. Rev. Oncog 16: 77–91 (2011)
Pratap J, Lian JB, Javed A, et al. Regulatory roles of Runx2 in metastatic
tumor and cancer cell interactions with bone. Cancer Metastasis Rev. 25:
589–600 (2006).
Ito Y & Miyazono K. RUNX transcription factors as key targets of TGF-β
superfamily signaling. Curr. Opin. Genet. Dev. 13: 43–47 (2003).
Stewart M, Terry A, Hu M, et al. Proviral insertions induce the expression
of bone-specific isoforms of PEBP2αA (CBFA1): evidence for a new myc
collaborating oncogene. Proc. Natl Acad. Sci. USA 94: 8646–8651 (1997).

44.

Wotton S, Stewart M, Blyth K, et al. Proviral insertion indicates a dominant
oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer Res. 62:
7181–7185 (2002).

45.

Stewart M, MacKay N, Cameron ER, et al. The common retroviral
insertion locus Dsi1 maps 30 kilobases upstream of the P1 promoter of the
murine Runx3/Cbfa3/Aml2 gene. J. Virol. 76: 4364–4369 (2002).
Uren AG, Kool J, Matentzoglu, et al. Large-scale mutagenesis in p19(ARF)and p53-deficient mice identifies cancer genes and their collaborative
networks. Cell 133: 727–741 (2008).
Browne G, Taipaleenmaki H, Bishop NM, et al. Runx1 Is Associated With
Breast Cancer Progression in MMTV-PyMT Transgenic Mice and its
Depletion In Vitro Inhibits Migration and Invasion. J. Cell. Physiol. 230:
2522–2532 (2015).

46.
47.

52

48.
49.

50.
51.
52.
53.
54.
55.
56.

Pratap J, Javed A, Languino LR, et al. The Runx2 osteogenic transcription
factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells
and controls cell invasion. Mol Cell Biol 25: 8581–8591 (2005).
Pratap J, Imbalanzo KM, Underwood JM, et al. Ectopic runx2 expression in
mammary epithelial cells disrupts formation of normal acini structure:
Implications for breast cancer progression. Cancer Res 69: 6807–6814
(2009).
Sokol ES, Sanduja S, Jin DX, et al. Perturbation-Expression Analysis
Identifies RUNX1 as a Regulator of Human Mammary Stem Cell
Differentiation. PLoS Comput Biol 11: e1004161 (2015).
Hong D, Messier TL, Tye CE, et al. Runx1 stabilizes the mammary
epithelial cell phenotype and prevents epithelial to mesenchymal
transition. Oncotarget 8(11): 17610-17627 (2017).
Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and
terminology: the devil is in the details. Nat Rev Cancer 12: 767–75 (2012).
Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells: perspectives on
current status and future directions: AACR Workshop on cancer stem
cells. Cancer Res. 66: 9339–44 (2006).
Ishiguro T, Ohata H, Sato A, et al. Tumor-derived spheroids: relevance to
cancer stem cells and clinical applications. Cancer Sci 108: 283–289 (2017).
Sachs N, de Ligt J, Kopper O, et al. A Living Biobank of Breast Cancer
Organoids Captures Disease Heterogeneity. Cell 172(1): 373-386 (2018).
Vlachogiannis G, Hedayat S, Vatsi A, et al. Patient-derived organoids
model treatment response of metastatic gastrointestinal cancers. Science
359(6378): 920-926 (2018).

53

